



Emerging Trends in Gastrointestinal Tract Disease Therapies

Guest Editors:

Dr. Puo-Hsien Le

Department of Gastroenterology
and Hepatology, Chang Gung
Memorial Hospital, Linkou
Branch, Taoyuan 333, Taiwan

Dr. Jenwei Chou

Division of Gastroenterology and
Hepatology, Department of
Internal Medicine, China Medical
University Hospital, Taichung
404327, Taiwan

Dr. Chen-Shuan Chung

Division of Gastroenterology and
Hepatology, Department of
Internal Medicine, Far Eastern
Memorial Hospital, New Taipei
City, Taiwan

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editors

Dear Colleagues,

In an era marked by unparalleled advancements in gastrointestinal (GI) tract disease therapies, this Special Issue is poised to capture and illuminate the significant progress characterizing this vibrant field. Our mission is to highlight the most recent trends, cutting-edge treatments, and transformative research shaping the future of GI disease management. We cordially invite submissions of original research and in-depth reviews. Our focus encompasses:

- Innovative therapeutic approaches—exploration of the latest pharmacological advancements, including biologics, small molecules, gene therapies, and their transformative impact on inflammatory bowel disease and other autoimmune-related GI disorders;
- Endoscopic breakthroughs—advancements in minimally invasive techniques, encompassing endoscopic bariatric therapy, endoscopic anti-reflux therapy, natural orifice transluminal endoscopic surgery, and more, and their efficacy in GI treatment;
- Gut microbiome research—insightful perspectives on the therapeutic roles of gut microbiota in GI diseases, unveiling novel interventions;



mdpi.com/si/195094

Dr. Puo-Hsien Le

Dr. Jenwei Chou

Dr. Chen-Shuan Chung

Guest Editors

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)